Evonile Pharma (500672) Q1 26/27 earnings summary

Executive summary

• Q1 FY26/27 revenue from operations was ₹1,038.1 million and profit for the period was ₹322.1 million; both exceeded the year-earlier quarter.

• Unaudited results were approved by the Board following Audit Committee review and received a limited review; auditors reported no matters causing them to believe the results contained a material misstatement.

Financial highlights

• Revenue from operations was ₹1,038.1 million vs ₹875.5 million YoY; total income was ₹1,125.5 million vs ₹981.6 million.

• Total expenses were ₹693.8 million vs ₹609.4 million YoY; profit before tax was ₹431.7 million vs ₹372.2 million.

• Profit for the period was ₹322.1 million vs ₹276.2 million YoY; total comprehensive income was ₹322.1 million vs ₹276.2 million.

• Other income was ₹87.4 million vs ₹106.1 million YoY; Q1 included no interest on income tax refunds, compared with ₹13.3 million in the prior quarter.

Segment performance

• Single operating segment: Pharmaceutical Business, with revenue generated from operations in India.

• One customer accounted for ₹532.9 million of revenue from traded goods in Q1, above 10% of total traded-goods revenue; the comparable Q1 prior-year figure was ₹390.4 million.